Diligence memo · auto-generated · as of July 2, 2026

NeuroX Innovations Inc.

NeuroX Innovations Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

NeuroX Innovations Inc. operates in Biotechnology, based in GREENWOOD VILLAGE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

NeuroX Innovations Inc. has raised $1.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $995K on 2022-12-19.

Most recent recorded round closed around 2022-12-19.

Valuation (modeled)modeled

Provath models NeuroX Innovations Inc. at approximately $12M (range $531K–$64M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 3.69× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.

Financing rhythm & timingmixed

Historic cadence: a new round about every 0 months.

Last raise 3.5 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 3.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 21% of Biotechnology peers (4293 compared).

Modeled value ranks above 21% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.